Financial incentives did not improve linkage to care or viral suppression in US study
Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease
Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection
Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation
Treatment cascades and viral load surveys show how African countries can maximise prevention benefits of HIV treatment
Circumcision is reducing HIV incidence in Uganda, Rakai community study shows
No HIV transmissions from HIV-positive partner seen in Australian gay couples study
US PEPFAR abstinence and faithfulness funding had no impact on sexual behaviour in Africa
HIV maturation inhibitor BMS-955176 looks promising in early study
